


## Tisolagiline

<b>Cat. No.:</b>	HY-127109
<b>CAS No.:</b>	1894207-44-3
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>17</sub> F <sub>3</sub> N <sub>2</sub> O
<b>Molecular Weight:</b>	322.32
<b>Target:</b>	Monoamine Oxidase
<b>Pathway:</b>	Neuronal Signaling
<b>Storage:</b>	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (310.25 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		3.1025 mL	15.5125 mL	31.0251 mL
		<b>5 mM</b>		0.6205 mL	3.1025 mL	6.2050 mL
<b>10 mM</b>		0.3103 mL	1.5513 mL	3.1025 mL		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.76 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tisolagiline (KDS2010) is a reversible MAO-B inhibitor used in Parkinson's disease research <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	MAO-B <sup>[1]</sup>

### REFERENCES

[1]. Nam MH, et al. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease. Neurotherapeutics. 2021 Jul;18(3):1729-1747.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA